GLP-1s and Muscle Loss: Where Are the Strength Trials?

Why It Matters

Understanding how GLP‑1s affect functional strength informs prescribing decisions and patient counseling, ensuring weight‑loss benefits are not offset by unintended performance declines.

Key Takeaways

• Strength trials for GLP‑1s are still emerging, not published yet.
• S‑Lite trial showed liraglutide plus aerobic exercise preserved knee strength.
• Semaglutide reduced fat, modest lean loss, but hand‑grip strength increased.
• Ongoing T‑Rex and LeanPrep studies pair GLP‑1s with resistance training.
• DEXA‑measured lean loss may overstate muscle loss; functional strength matters.

Summary

The discussion centers on the paucity of dedicated strength‑training trials for GLP‑1 agonists and the clinical anxiety that these drugs may cause excessive muscle loss. While weight‑loss benefits are clear, patients and clinicians worry whether lean‑mass reductions translate into functional weakness, especially for athletes or older adults.

Existing data provide mixed signals. The 2021 S‑Lite trial in Copenhagen randomized obese participants to liraglutide, aerobic exercise, both, or placebo; the combination preserved and even improved knee‑extension strength, while liraglutide alone did not cause a meaningful decline despite greater weight loss. A 2024 follow‑up showed exercise also protected hip bone density, a typical loss in pure diet‑induced weight loss. In a separate semaglutide study, participants lost 18% fat, 5% lean mass, yet hand‑grip strength rose 4.5 kg, suggesting intramuscular fat reduction may enhance functional output.

Future research aims to fill the gap. The Australian T‑Rex trial and the LeanPrep study are pairing GLP‑1s with structured resistance training, using strength endpoints such as one‑rep maxes and grip strength. Parallel investigations like the BELIEVE trial (bimagrumab + semaglutide) and early-phase myostatin‑inhibitor trials (trevogrumab, obasarm) explore whether pharmacologic muscle‑building can offset any lean loss, though grip strength often remains unchanged.

Clinicians should interpret DEXA‑derived lean‑mass changes cautiously, recognizing that water, glycogen, and measurement variability can masquerade as muscle loss. Emphasizing regular resistance exercise—even modest, twice‑weekly sessions—appears to preserve functional strength and bone health, mitigating theoretical risks while patients reap the metabolic advantages of GLP‑1 therapy.

Original Description

If GLP-1 medications cause the muscle loss everyone worries about, the cleanest way to settle it would be a trial with strength as the primary endpoint: drug versus placebo, training versus no training. So where are those trials? Jordan and Dr. Austin Baraki walk through what the published evidence actually shows and what is still coming.

We cover the Copenhagen trial published in the New England Journal of Medicine in 2021, where the drug-alone group lost more weight without a meaningful decline in knee-extensor strength, plus the 2024 follow-up on bone density. We get into the semaglutide data on grip strength and intramuscular fat, the BELIEVE trial pairing a myostatin-pathway antibody with semaglutide, the enobosarm work, and the trials still in progress (T-REX, a lean-mass prep study, and Regeneron’s myostatin-inhibitor programs). Most of these use grip strength or stair-climb power rather than a one-rep max, which is part of the problem.

The throughline is measurement. Much of the muscle-loss panic is an artifact of DEXA reading “lean mass” as if it were contractile muscle, when force production depends on training and neural coordination the drug does not provide. Austin closes with how he frames the strength conversation with patients starting a GLP-1: keep training, use the muscle you have, and adjust if early signs say otherwise. For infotainment purposes only; we are not your doctors. Full AMA episode and reference list linked below.

Resources:

Subscribe to BBM Plus for the full unabridged Direct Line: https://barbellmedicine.supercast.com/

Barbell Medicine coaching and templates: https://www.barbellmedicine.com/

Signal book pre-order: https://www.barbellmedicine.com/shop/learning/signal/

Lundgren J.R. et al. 2021 (S-LiTE trial). Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 384(18):1719-1730.

https://pubmed.ncbi.nlm.nih.gov/33951361/

Jensen S.B.K. et al. 2024. Bone health after exercise alone, GLP-1 receptor agonist, or combination: follow-up of the S-LiTE trial. JAMA Netw Open 7(6):e2416775. https://pubmed.ncbi.nlm.nih.gov/38869898/

Heymsfield S.B. et al. 2024 (BELIEVE trial). Bimagrumab and semaglutide for treatment of obesity. NEJM Evid

Pratley R.E. et al. 2024 (T-REX preliminary data).